A
AcelRx Pharmaceuticals Inc
F:R5XA
AcelRx Pharmaceuticals Inc
F:R5XA
Price:
0.748
EUR
-0.27%
Market Closed
Market Cap:
€12.7m
Relative Value
There is not enough data to reliably calculate the relative value of R5XA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
R5XA
Relative Value
Base Case
Not Available
Multiples Across Competitors
R5XA Competitors Multiples
AcelRx Pharmaceuticals Inc Competitors
AcelRx Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
A
|
AcelRx Pharmaceuticals Inc
F:R5XA
|
310.3m EUR | 589.4 | -13.8 | -18.2 | -17.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
923.3B USD | 14.2 | 44.7 | 30.2 | 32.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
582.8B USD | 6.2 | 21.7 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
253.4B CHF | 4.1 | 19.6 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP | 5.1 | 29.3 | 16.2 | 22.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.8B CHF | 5.3 | 21.4 | 13.2 | 17 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.8B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.7B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.7B USD | 2.5 | 16.8 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
